Why Trader’s Are Watching: Sterling Construction Co. Inc. (NASDAQ:STRL), Lion Biotechnologies (NASDAQ:LBIO), ScanSource (NASDAQ:SCSC), Acorda Therapeutics (NASDAQ:ACOR), Nautilus Inc. (NYSE:NLS)

Sterling Construction Company, Inc. (NASDAQ:STRL) announced that Paul J. Varello, who was elected acting CEO in February, has entered into a multi-year employment agreement with the Company effective March 9, 2015. On Thursday shares of Sterling Construction Co. Inc. (NASDAQ:STRL) closed at $3.13. Company’s sales growth for last 5 years was 6.00% and EPS growth for next 5 years is recorded as 11.00%.

Piper Jaffray assumed coverage on shares of Lion Biotechnologies, Inc. (NASDAQ:LBIO) in a report issued on Monday,TheFlyOnTheWall.com reports. The firm issued an overweight rating and a $21.00 target price on the stock. Lion Biotechnologies, Inc. (NASDAQ:LBIO) in last trading activity moved up 9.93% to close at $12.40. Company weekly performance is 29.71% while its quarterly performance stands at 110.17%. Lion Biotechnologies, Inc. (NASDAQ:LBIO) is 3.33% away from its 52 week high.

ScanSource Communications, a sales unit of ScanSource Inc. (NASDAQ:SCSC) announced it is now offering ShoreTel Sky®, a cloud-based solution that provides businesses a high degree of flexibility, connectivity and seamless integration with their business-critical applications. With this, ScanSource Communications becomes the only distributor to offer both ShoreTel premises- and cloud-based solutions to resellers. On last trading day ScanSource, Inc. (NASDAQ:SCSC) moved up 1.92% to close at $37.65. Its volatility for the week is 1.93% while volatility for the month is 2.35%. SCSC’s sales growth for past 5 years was 9.50% and its EPS growth for past 5 years was 9.80%. ScanSource, Inc. (NASDAQ:SCSC) monthly performance is 3.24%.

On March 9, it was reported that, A hedge fund’s attempt to invalidate Acorda Therapeutics Inc. (NASDAQ:ACOR) drug patents under the America Invents Act as an investment strategy to lower the company’s stock price should have biotechnology companies on alert for similar challenges, attorneys say, although the tactic makes financial sense only in rare cases. Acorda Therapeutics, Inc. (NASDAQ:ACOR) has 1.80% insider ownership. In last trading activity company’s stock closed at $34.25.

Nautilus, Inc. (NYSE:NLS)’s Chief Executive Officer Bruce M. Cazenave, Sid Nayar, Chief Financial Officer, and William B. McMahon, Chief Operating Officer, presented at the 27th Annual ROTH Conference on March 8-11, 2015, at the Ritz Carlton Laguna Niguel. On last trading day Nautilus Inc. (NYSE:NLS) moved up 3.66% to close at $15.85. Its volatility for the week is 3.18% while volatility for the month is 2.85%. NLS’s sales growth for past 5 years was 7.70% and its EPS growth for past 5 years was 25.00%. Nautilus Inc. (NYSE:NLS) monthly performance is 5.11%.

Leave a Reply

Your email address will not be published. Required fields are marked *